Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT ID: NCT07161037
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
24 participants
INTERVENTIONAL
2025-11-19
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
NCT07022119
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT05312879
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
NCT04340362
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
NCT05324410
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
NCT04705051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VX-407
Participants will receive VX-407 for up to 52 weeks.
VX-407
Tablets for oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-407
Tablets for oral administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to comply with scheduled visits and other study procedures
* Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening
* Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73 square meter (m\^2)
Exclusion Criteria
* History of solid organ or bone marrow transplantation or nephrectomy
* Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Kidney Research
Alabaster, Alabama, United States
University of Alabama at Birmingham- Nephrology Research Clinic
Birmingham, Alabama, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
UCSF Clinical Research Center at Parnassus
San Francisco, California, United States
Nephrology & Hypertension Associates, PC
Middlebury, Connecticut, United States
Yale University - Yale Nephrology Clinical Research Clinic
New Haven, Connecticut, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Emory School of Medicine - Renal Division
Atlanta, Georgia, United States
Renal Associates
Columbus, Georgia, United States
UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
Chicago, Illinois, United States
University of Iowa Health Care Medical Center- Nephrology
Iowa City, Iowa, United States
The University of Kansas Medical Center Division of Nephrology
Kansas City, Kansas, United States
University of Maryland Medical Center - General Clinical Research Center
Baltimore, Maryland, United States
Tufts Medical Center
Boston, Massachusetts, United States
University of Minnesota -Clinics and Surgery Center (CSC) - Endocrine Clinic
Minneapolis, Minnesota, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
DaVita Kidney Care - Las Vegas
Las Vegas, Nevada, United States
Columbia University Medical Center/NYP
New York, New York, United States
UVM Medical Center - 1 South Prospect Street
Burlington, Vermont, United States
Universite Catholique de Louvain - Nephrology
Brussels, , Belgium
McGill University Health Centre
Montreal, , Canada
Centre Hospitalier Regional Universitaire (CHRU) Brest
Brest, , France
Queen Elizabeth Hospital Birmingham
Birmingham, , United Kingdom
King's College Hospital - Pulmonology
London, , United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital - Nephrology
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517393-13-00
Identifier Type: OTHER
Identifier Source: secondary_id
VX24-407-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.